Citi is opening an “Upside 90-Day Catalyst Watch” on Pfizer, citing upside to 2024 guidance as the potential catalyst. Pfizer’s 2024 guidance “looks highly conservative,” according to the analyst, who notes that the firm’s 2024 estimates are about 11% above the top end of the non-GAAP EPS guidance range the company issued. However, the firm keeps a Neutral rating and $28 price target on Pfizer shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PFE: